Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum Resistant Urothelial Bladder Cancer

NCT02351739 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

78

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Urothelial Carcinoma

Interventions

DRUG: pembrolizumab
DRUG: ACP-196 in combination with pembrolizumab

Sponsor

Acerta Pharma BV

Collaborators

[object Object]